PMID- 36818343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230224
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 10
DP  - 2023
TI  - Mesenchymal stem cell-based therapy for non-healing wounds due to chronic 
      limb-threatening ischemia: A review of preclinical and clinical studies.
PG  - 1113982
LID - 10.3389/fcvm.2023.1113982 [doi]
LID - 1113982
AB  - Progressive peripheral arterial disease (PAD) can result in chronic 
      limb-threatening ischemia (CLTI) characterized by clinical complications 
      including rest pain, gangrene and tissue loss. These complications can propagate 
      even more precipitously in the setting of common concomitant diseases in patients 
      with CLTI such as diabetes mellitus (DM). CLTI ulcers are cutaneous, non-healing 
      wounds that persist due to the reduced perfusion and dysfunctional 
      neovascularization associated with severe PAD. Existing therapies for CLTI are 
      primarily limited to anatomic revascularization and medical management of 
      contributing factors such as atherosclerosis and glycemic control. However, many 
      patients fail these treatment strategies and are considered "no-option," thereby 
      requiring extremity amputation, particularly if non-healing wounds become 
      infected or fulminant gangrene develops. Given the high economic burden imposed 
      on patients, decreased quality of life, and poor survival of no-option CLTI 
      patients, regenerative therapies aimed at neovascularization to improve wound 
      healing and limb salvage hold significant promise. Cell-based therapy, 
      specifically utilizing mesenchymal stem/stromal cells (MSCs), is one such 
      regenerative strategy to stimulate therapeutic angiogenesis and tissue 
      regeneration. Although previous reviews have focused primarily on 
      revascularization outcomes after MSC treatments of CLTI with less attention given 
      to their effects on wound healing, here we review advances in pre-clinical and 
      clinical studies related to specific effects of MSC-based therapeutics upon 
      ischemic non-healing wounds associated with CLTI.
CI  - Copyright (c) 2023 Huerta, Voza, Ortiz, Liu and Velazquez.
FAU - Huerta, Carlos Theodore
AU  - Huerta CT
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Voza, Francesca A
AU  - Voza FA
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Ortiz, Yulexi Y
AU  - Ortiz YY
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
FAU - Liu, Zhao-Jun
AU  - Liu ZJ
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
AD  - Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, 
      FL, United States.
FAU - Velazquez, Omaida C
AU  - Velazquez OC
AD  - DeWitt Daughtry Family Department of Surgery, University of Miami Miller School 
      of Medicine, Miami, FL, United States.
AD  - Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, 
      FL, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230201
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9930203
OTO - NOTNLM
OT  - Peripheral Arterial Disease
OT  - cell-based therapy
OT  - chronic limb-threatening ischemia
OT  - critical limb ischemia
OT  - diabetic wound
OT  - mesenchymal stem (stromal) cell
OT  - stem cell therapy
OT  - wound healing
COIS- CH, FV, and YO have no commercial or financial relationships that could be 
      construed as a potential conflict of interest. Z-JL and OV declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: the E-selectin gene modification technologies 
      described in referenced articles by Z-JL and OV were developed in our research 
      laboratory and patented/licensed by the University of Miami. This technology is 
      currently under pre-clinical development by Ambulero Inc., a new start-up company 
      out of the University of Miami that focuses on developing new vascular treatments 
      for ischemic conditions. Co-authors, Z-JL and OV serve as consultants and 
      scientific and medical advisory officers in Ambulero Inc.
EDAT- 2023/02/24 06:00
MHDA- 2023/02/24 06:01
PMCR- 2023/01/01
CRDT- 2023/02/23 09:48
PHST- 2022/12/01 00:00 [received]
PHST- 2023/01/12 00:00 [accepted]
PHST- 2023/02/23 09:48 [entrez]
PHST- 2023/02/24 06:00 [pubmed]
PHST- 2023/02/24 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2023.1113982 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2023 Feb 1;10:1113982. doi: 10.3389/fcvm.2023.1113982. 
      eCollection 2023.